Journal of Clinical Oncology
Articles in this Issue
Real-world treatment patterns and overall survival in recurrent/metastatic head and neck squamous cell carcinoma following treatment with immune checkpoint inhibitor and platinum-based chemotherapy.
6038 Background: Treatments for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) include immune chec...
Impact of neoadjuvant durvalumab (D) on tumor microenvironment (TME) features and their association with event-free survival (EFS) in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
8015 Background: In AEGEAN, perioperative D + neoadj CT improved EFS and pathological complete response vs neoadj CT alone...
Genomic profiling of Burkitt lymphoma in adults: Novel molecular insights and implications for outcomes.
7085 Background: The real-world treatment outcomes of Burkitt lymphoma (BL) from low-middle income countries appear to be...
Preclinical investigations and first-in-human phase I trial of KP-483 in solid tumors: Safety, antitumor activity, and preliminary efficacy.
2659 Background: KP-483 is a novel small-molecule antagonist of the E-type prostanoid receptor 4 (EP4) that potentially ex...
Extrapulmonary small cell carcinoma treated with conventional or tumor-targeted topoisomerase I inhibition plus ATR blockade: Clinical outcomes and molecular correlates.
3027 Background: Extrapulmonary Small Cell Carcinoma (EPSCC) is a rare (0.1–0.4% of all cancers), aggressive neuroendocrin...
Clinical utility of repeat next-generation sequencing in patients with driver-negative non-small cell lung cancer: A report from the LC-SCRUM-TRY screening platform.
8626 Background: While precision medicine targeting driver oncogenes has improved clinical outcome of non-small cell lung...
Real-world incidence and clinical outcomes of trastuzumab/pertuzumab-induced thrombocytopenia in adjuvant HER2-positive breast cancer: 8-year retrospective multicenter study.
e23379 Background: Trastuzumab, alone or with pertuzumab, is standard adjuvant therapy for HER2-positive breast cancer. Re...
CV CARE: Cardiovascular care of androgen-related effects in prostate cancer patients.
e13581 Background: Cardiovascular disease (CVD) is a leading cause of death among prostate cancer (PC) survivors, and trea...
Deep learning identification of high-risk lung adenocarcinoma histologic subtypes: A decision-support tool for treatment planning.
e20022 Background: Lung adenocarcinoma (LUAD) is the most common lung cancer subtype. Solid and micropapillary patterns re...
Targeting macrophage migration inhibitory factor: A phase 2 and pharmacodynamic study of sitagliptin in patients with progressive grade 4 gliomas.
TPS2099 Background: One mechanism of immunosuppression in the glioblastoma (GBM) microenvironment involves systemic and lo...
A phase 3, randomized, double-arm, open-label, controlled study of ASP-1929 photoimmunotherapy (PIT) versus physician’s choice standard of care (SOC) for patients with locoregional, recurrent head and neck squamous cell carcinoma (HNSCC).
6080 Background: Locoregional recurrence is the main cause of morbidity and mortality in HNSCC, yet therapeutic choices ar...
Interrogating acquired PD-1 resistance through BET bromodomain inhibition in hepatocellular carcinoma murine models.
e16154 Background: Immune checkpoint inhibitors targeting the PD-1 pathway have become the standard of care for hepatocell...
Impact of a real-time targeted expert outreach model on conversion of biomarker results to precision treatments.
e23390 Background: Previous publications reported low rates of converting positive biomarker results into appropriate trea...
Detection of organophosphorus pesticide residues in breast cancer tissue: A translational integrated environmental exposure study.
e12580 Background: Geographic variation in cancer incidence reflects differences in exposure to environmental carcinogens....
Real-world toxicity outcomes with adjuvant pembrolizumab following nephrectomy for renal cell carcinoma.
e23447 Background: Adjuvant pembrolizumab improves overall and disease-free survival in high-risk renal cell carcinoma (RC...
From unstructured oncology EHRs to regulatory-grade real-world evidence: A next-generation registry approach.
e23425 Background: Real-world evidence (RWE) derived from oncology electronic health records (EHRs) is increasingly used t...
Modeling early gastric cancer evolution following <i>ARID1A</i> loss in Latino patient-derived organoids.
e16144 Background: Gastric cancer remains a leading cause of cancer mortality worldwide, with disproportionately worse out...
Correlation of tumor grade with increased CD3+ t-cell and FOXP3+ regulatory T-cell infiltration in neuroendocrine neoplasms.
e15186 Background: Neuroendocrine neoplasms (NENs) comprise a biologically heterogenous group of malignancies with diverse...
E-PROs in oncology: Improving treatment adherence to treatment while reducing emergency care and costs for patients with gastrointestinal malignancies receiving systemic therapy.
11109 Background: Patients with cancer undergoing systemic therapy are prone to experience symptom-related complications w...
Nivolumab plus lenvatinib for unresectable anaplastic thyroid cancer: Results of the phase 2 NAVIGATION study.
6021 Background: Anaplastic thyroid cancer (ATC) is one of the most aggressive and lethal malignancies, characterized by l...
Differential gene detection and turnaround time between tissue and Guardant360 liquid biopsy next-generation sequencing across solid malignancies.
e15066 Background: Circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is increasingly used for genomic profili...
Diagnostic and prognostic value of plasma D-dimer levels for metastasis and survival in gastric cancer: A systematic review and meta-analysis.
e16089 Background: Gastric cancer (GC) is frequently associated with hypercoagulability, yet the clinical utility of D-dim...
Comprehensive profiling of antibody-drug conjugate target expression in epithelial ovarian cancer with pre- and post-ADC longitudinal assessment.
5594 Background: Antibody–drug conjugates (ADCs) are increasingly used in ovarian cancer, yet target expression may evolve...
Prognostic significance of ctDNA detection at the time of relapse during melanoma surveillance.
e21543 Background: Circulating tumor DNA (ctDNA) is an emerging biomarker of progression and relapse in multiple cancers....
Neoantigen prediction and reactivity of cerebrospinal fluid–human-derived tumor reactive T cells (CSF-TRT cells) in leptomeningeal disease (LMD) from solid tumors.
2030 Background: Leptomeningeal disease (LMD) is a devastating complication of metastases and its incidence is increasing....